Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine model

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2249-2256

  Cui, Song ^a   Song, Xian Tao ^a   Ding, Chao ^b   Meng, Li Jun ^c   Lv, Shu Zheng ^a   Li, Kefeng ^d,e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Department of Cardiology Huimin People s Hospital   (China)

^c Binzhou Central Hospital   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Tianjin SunnyPeak Biotech Co Ltd   (China)

Author keywords

Anti CD34; Endothelialization; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CD34 ANTIGEN; CLOPIDOGREL; ENDOGLIN; RAPAMYCIN; LEUKOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; ENDOGLIN ANTIBODY COATED STENT; ENDOTHELIAL DYSFUNCTION; INFLAMMATION; INTRAVASCULAR ULTRASOUND; MORPHOMETRICS; NEOINTIMA; NONHUMAN; PIG; RESTENOSIS; SCANNING ELECTRON MICROSCOPY; STENT; ANATOMY; ANIMAL; ARTERY; DRUG EFFECTS; GRAFT OCCLUSION, VASCULAR; IMMUNOLOGY; PATHOLOGY; VASCULAR ENDOTHELIUM;

ANATOMY, CROSS-SECTIONAL; ANIMALS; ANTIGENS, CD; ANTIGENS, CD34; ARTERIES; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; GRAFT OCCLUSION, VASCULAR; INFLAMMATION; NEOINTIMA; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SWINE;

EID: 84929179004     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S81257     Document Type: Article

References (37)

1. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003;89(2):218–224.
2. Scott NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev. 2006;58(3):358–376.
3. Morice MC, Serruys PW, Sousa JE, et al; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773–1780.
4. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109(16):1942–1947.
5. Chang JY, Sehgal SN, Bansbach CC. FK506 and rapamycin: novel pharmacological probes of the immune response. Trends Pharmacol Sci. 1991;12(6):218–223.
6. Kirtane AJ, Leon MB. Clinical use of sirolimus-eluting stents. Cardiovasc Drug Rev. 2007;25(4):316–332.
7. Qiao Y, Bian Y, Yan X, Liu Z, Chen Y. Efficacy and safety of sirolimus-eluting stents versus bare-metal stents in coronary artery disease patients with diabetes: a meta-analysis. Cardiovasc J Afr. 2013;24(7):274–279.
8. Rodriguez-Granillo A, Rubilar B, Rodriguez-Granillo G, Rodriguez AE. Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol. 2011;3(3):84–92.
9. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354(5):483–495.
10. Garg S, Duckers HJ, Serruys PW. Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice? Eur Heart J. 2010;31(9):1032–1035.
11. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation. 2002;106(10):1199–1204.
12. Harraz M, Jiao C, Hanlon HD, Hartley RS, Schatteman GC. CD34-blood-derived human endothelial cell progenitors. Stem Cells. 2001;19(4):304–312.
13. Yamashita H, Ichijo H, Grimsby S, Morén A, ten Dijke P, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem. 1994;269(3):1995–2001.
14. Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267(27):19027–19030.
15. Bernabeu C, Conley BA, Vary CP. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem. 2007;102(6):1375–1388.
16. Kapur NK, Wilson S, Yunis AA, et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012;125(22):2728–2738.
17. van Laake LW, van den Driesche S, Post S, et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation. 2006;114(21):2288–2297.
18. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 2010;86(1):12–19.
19. Cui S, Liu JH, Song XT, et al. A novel stent coated with antibodies to endoglin inhibits neointimal formation of porcine coronary arteries. Biomed Res Int. Epub 2014 May 4.
20. Li HH, Kedar V, Zhang C, et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest. 2004;114(8):1058–1071.
21. Ma X, Hibbert B, Dhaliwal B, et al. Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc Res. 2010;86(2):338–345.
22. Steigerwald K, Merl S, Kastrati A, et al. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials. 2009;30(4):632–637.
23. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267–274.
24. Hong YJ, Jeong MH, Lee SR, et al. Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model. J Korean Med Sci. 2007;22(5):802–809.
25. Moukarbel GV, Burket MW. Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent. Expert Rev Med Devices. 2015;12(2):157–162.
26. Nakamura D, Lee Y, Yoshimura T, et al. Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study. EuroIntervention. 2014;10(8):924–933.
27. Pfisterer ME. Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised. Circulation. 2008;118(11):1117–1119.
28. Ertaş G, van Beusekom HM, van der Giessen WJ. Late stent thrombosis, endothelialisation and drug-eluting stents. Neth Heart J. 2009; 17(4):177–180.
29. Houtgraaf JH, Duckers HJ. Endothelial progenitor cell (EPC) capture to aid vascular repair following coronary stenting: a new frontier in stent technology? EuroIntervention. 2008;4(Suppl C):C67–C71.
30. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952–958.
31. Valluru M, Staton CA, Reed MW, Brown NJ. Transforming growth factor-β and endoglin signaling orchestrate wound healing. Front Physiol. 2011;2:89.
32. Lastres P, Letamendía A, Zhang H, et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol. 1996;133(5):1109–1121.
33. Park S, Dimaio TA, Liu W, Wang S, Sorenson CM, Sheibani N. Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-β signaling pathways. J Cell Sci. 2013;126(Pt 6):1392–1405.
34. Anderson P, Carrillo-Gálvez AB, García-Pérez A, Cobo M, Martín F. CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities. PLoS One. 2013;8(10):e76979.
35. van Beusekom HM, Ertaş G, Sorop O, Serruys PW, van der Giessen WJ. The Genous™ endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries. Catheter Cardiovasc Interv. 2012;79(2):231–242.
36. Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24(10):1891–1896.
37. Li J, Li D, Gong F, Jiang S, Yu H, An Y. Anti-CD133 antibody immobilized on the surface of stents enhances endothelialization. Biomed Res Int. Epub 2014 Mar 10.